Ningbo David Medical Device Co., Ltd. (SHE:300314)
China · Delayed Price · Currency is CNY 10.72
-0.27 (-2.46%)
May 21, 2026, 3:04 PM CST
SHE:300314 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 570.25 | 578.62 | 516.93 | 606.83 | 496.58 | 469.87 |
Other Revenue | 5.41 | 5.41 | 10.1 | 11.47 | 9.46 | 4.26 |
| 575.66 | 584.03 | 527.03 | 618.3 | 506.04 | 474.13 | |
Revenue Growth (YoY) | 16.80% | 10.82% | -14.76% | 22.18% | 6.73% | 3.18% |
Cost of Revenue | 277.56 | 273.01 | 233.47 | 263.61 | 210.28 | 185.25 |
Gross Profit | 298.11 | 311.02 | 293.55 | 354.68 | 295.76 | 288.88 |
Selling, General & Admin | 172.44 | 174.81 | 172.44 | 172.15 | 155.19 | 166.5 |
Research & Development | 55.94 | 59.3 | 55.46 | 48.06 | 45.87 | 49.69 |
Other Operating Expenses | 5.86 | 4.56 | 5.03 | 6.72 | 7.98 | 6.81 |
Operating Expenses | 234.96 | 239.96 | 233.16 | 227.43 | 210.26 | 223.27 |
Operating Income | 63.15 | 71.06 | 60.39 | 127.25 | 85.5 | 65.61 |
Interest Expense | -0.05 | -0.43 | -0.47 | -0.6 | -0.35 | -0.03 |
Interest & Investment Income | 25.61 | 25.84 | 10.71 | 25.87 | 5.39 | 18.9 |
Currency Exchange Gain (Loss) | -5.72 | -5.72 | 0.83 | 6.33 | 17.05 | -2.86 |
Other Non Operating Income (Expenses) | -8.45 | -0.48 | -0.46 | -0.3 | -0.27 | -0.23 |
EBT Excluding Unusual Items | 74.53 | 90.27 | 71.01 | 158.55 | 107.31 | 81.38 |
Impairment of Goodwill | - | - | -0.52 | -1.53 | - | - |
Gain (Loss) on Sale of Investments | 3.2 | 1.78 | -10.06 | 0.26 | -4.88 | 0.69 |
Gain (Loss) on Sale of Assets | -0.36 | -0.39 | -0.01 | -0.23 | 0.02 | 0.12 |
Asset Writedown | -0.02 | -0.02 | -0.01 | -0.08 | -0.02 | -0.04 |
Other Unusual Items | 6.77 | 7.02 | 2.98 | 9.24 | 9.49 | 5.05 |
Pretax Income | 84.12 | 98.66 | 63.38 | 166.22 | 111.92 | 87.19 |
Income Tax Expense | 9.75 | 11.6 | 6.12 | 18.61 | 14.56 | 6.99 |
Net Income | 74.37 | 87.05 | 57.26 | 147.61 | 97.36 | 80.21 |
Net Income to Common | 74.37 | 87.05 | 57.26 | 147.61 | 97.36 | 80.21 |
Net Income Growth | 78.25% | 52.02% | -61.21% | 51.62% | 21.39% | -41.11% |
Shares Outstanding (Basic) | 290 | 290 | 286 | 289 | 286 | 286 |
Shares Outstanding (Diluted) | 290 | 290 | 286 | 289 | 286 | 286 |
Shares Change (YoY) | 1.40% | 1.35% | -1.08% | 1.08% | -0.04% | -1.14% |
EPS (Basic) | 0.26 | 0.30 | 0.20 | 0.51 | 0.34 | 0.28 |
EPS (Diluted) | 0.26 | 0.30 | 0.20 | 0.51 | 0.34 | 0.28 |
EPS Growth | 75.79% | 50.00% | -60.78% | 50.00% | 21.43% | -40.43% |
Free Cash Flow | 42.21 | 34.22 | -45.82 | 94.81 | 61.79 | 44.95 |
Free Cash Flow Per Share | 0.14 | 0.12 | -0.16 | 0.33 | 0.22 | 0.16 |
Dividend Per Share | 0.080 | 0.080 | 0.087 | 0.180 | 0.150 | 0.100 |
Dividend Growth | -8.05% | -8.05% | -51.67% | 20.00% | 50.00% | -33.33% |
Gross Margin | 51.79% | 53.25% | 55.70% | 57.36% | 58.45% | 60.93% |
Operating Margin | 10.97% | 12.17% | 11.46% | 20.58% | 16.89% | 13.84% |
Profit Margin | 12.92% | 14.91% | 10.87% | 23.87% | 19.24% | 16.92% |
Free Cash Flow Margin | 7.33% | 5.86% | -8.70% | 15.33% | 12.21% | 9.48% |
EBITDA | 83.84 | 92.48 | 84.68 | 154.57 | 108.93 | 89.76 |
EBITDA Margin | 14.56% | 15.83% | 16.07% | 25.00% | 21.53% | 18.93% |
D&A For EBITDA | 20.69 | 21.41 | 24.29 | 27.32 | 23.43 | 24.15 |
EBIT | 63.15 | 71.06 | 60.39 | 127.25 | 85.5 | 65.61 |
EBIT Margin | 10.97% | 12.17% | 11.46% | 20.58% | 16.89% | 13.84% |
Effective Tax Rate | 11.59% | 11.76% | 9.65% | 11.20% | 13.01% | 8.01% |
Revenue as Reported | 575.66 | 584.03 | 527.03 | 618.3 | 506.04 | 474.13 |
Advertising Expenses | - | 9.38 | 3.22 | 4.51 | 3.32 | 4.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.